



Cancer Immunotherapy: Current Advancements and Future Perspectives

Guest Editors:

Dr. Stefano Forte

Istituto Oncologico del
Mediterraneo, 95029 Viagrande,
Italy

Dr. Gianluca Ferini

REM Radioterapia, 95029
Viagrande, Italy

Deadline for manuscript
submissions:

31 December 2025

Message from the Guest Editors

Dear Colleagues,

The goal of immune therapy is to elicit and maintain an immune mediation response to cancer cells to establish a self-sustained process. This approach demonstrates its significant effectiveness in diseases where therapeutic options are not particularly effective. Unfortunately, the percentage of patients who benefit from these treatments remains limited. Regarding radiotherapy, it is well-known that it can induce abscopal and bystander effects by recruiting immune cells against the tumor. Unfortunately, such responses are episodic and not systematically inducible. These may be synergized and promoted by immunotherapy. Bench-to-bedside and vice versa findings are welcome in this Special Issue to shed light on the rationale and mechanisms of these new therapeutic opportunities.


The weapon of immunotherapy should be made effective for a larger number of patients. It is also important to effectively combine immunotherapy with chemotherapy, radiotherapy or targeted therapies aiming towards a complete and sustainable disease eradication.

Dr. Stefano Forte

Dr. Gianluca Ferini

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W,F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [PubMed](#), [PMC](#), [Embase](#), and [other databases](#).

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)